Valion Bio Taps Legal-Science Hybrid to Drive Growth Strategy

SAN ANTONIO, TX – May 04, 2026 – Clinical-stage immunotherapeutics company Valion Bio, Inc. (Nasdaq: VBIO) has appointed Melinda Lackey as its new General Counsel and Senior Vice President of Legal Affairs, a move that signals a calculated acceleration of its multifaceted growth strategy. The appointment is not a routine leadership shuffle; it is a strategic placement of a legal executive whose unique background in science, intellectual property, and public company governance is tailor-made for Valion’s current, critical phase of development.

The San Antonio-based company is simultaneously advancing on three complex fronts: pushing its lead drug candidate, Entolimod™, through a challenging regulatory pathway for Acute Radiation Syndrome (ARS); scaling its wholly-owned manufacturing subsidiary, Velocity Bioworks; and executing a significant capital raise. Ms. Lackey’s nearly two decades of experience at the intersection of these domains makes her a pivotal addition to the leadership team.

A Strategic Appointment for a Pivotal Moment

Valion Bio's trajectory demands a leader who can navigate the intricate legal and regulatory frameworks that govern high-stakes biopharmaceutical development. The company is betting that Lackey is that leader. Her appointment comes as Valion works to deploy a financing package exceeding $90 million, secured in late 2025, aimed at funding these parallel initiatives.

"Melinda's appointment reflects Valion Bio's direction," said Michael K. Handley, Chief Executive Officer of Valion Bio, in a statement. He emphasized her career path—from a research bench at MD Anderson to senior legal leadership at a Nasdaq-listed cell therapy company—as a key asset. "As we work to execute our capital raise, advance Entolimod™ through the Animal Rule pathway, and scale Velocity Bioworks, having an in-house General Counsel with her depth of scientific literacy, IP acumen, and public company experience is a strategic imperative."

Lackey's recent role as Senior Vice President of Legal & Administration at Alaunos Therapeutics, another clinical-stage oncology company, provided direct experience managing the legal functions of a publicly traded immunology firm. There, she handled complex clinical development, regulatory strategy, and capital markets obligations—a trifecta of challenges central to Valion Bio's current mission.

The Leader Blurring Science and Law

Melinda Lackey’s career embodies a growing trend in the biotech industry: the fusion of deep scientific understanding with sophisticated legal expertise. Before earning her J.D. from the University of Houston Law Center, she worked as a Research Technician at UT MD Anderson Cancer Center and a Research Associate at the University of Texas Health Science Center, holding a Master of Science in Medical Microbiology and Immunology.

This foundation in the lab provides a crucial lens for her legal work. After transitioning to law, she honed her skills at nationally recognized IP and life sciences practices, including Winston & Strawn LLP and Howrey LLP, where she focused on patent litigation and IP portfolio strategy. Her subsequent in-house roles at Kuur Therapeutics, a cellular immunotherapy company acquired by a global biopharma firm, and later at Alaunos, solidified her expertise in the legal architecture of next-generation immunology platforms.

This hybrid profile is invaluable for a company like Valion, whose core asset, Entolimod™, is a complex biologic—a TLR5 agonist designed to activate the body's innate immunity. Protecting such an asset requires more than just standard legal defense; it demands a granular understanding of the underlying science to build a robust intellectual property fortress and navigate the scientific arguments required by regulatory bodies like the FDA.

Navigating the High-Stakes Animal Rule Pathway

One of the most significant hurdles for Valion Bio is advancing Entolimod™ for Acute Radiation Syndrome (ARS) via the FDA's Animal Rule. This specific regulatory pathway (21 CFR 314 Subpart I) is reserved for drugs intended to treat life-threatening conditions where human efficacy trials are unethical or infeasible, such as exposure to a radiological or nuclear agent. Approval is instead based on robust efficacy data from well-controlled animal studies and safety data from human trials.

While the Animal Rule provides a path to market, it is notoriously rigorous. The FDA requires a well-understood mechanism of action, demonstrated effect in appropriate animal models, and a clear link between the animal study endpoint and the desired human benefit—typically survival. Guiding a product through this process requires constant and meticulous engagement with the agency.

Valion Bio is not the first to travel this road. Several countermeasures for hematopoietic ARS, such as Neupogen and Neulasta, were approved under this rule after being repurposed. However, significant gaps remain in the nation's medical countermeasure arsenal, particularly for prophylaxis or for treating other effects of radiation exposure. Entolimod™, which has already received Fast Track and Orphan Drug designations from the FDA for this indication, aims to fill one of these gaps. Lackey's experience with clinical-stage regulatory strategy will be instrumental in steering the company through the unique demands of the Animal Rule pathway, a process that is as much a legal and procedural challenge as it is a scientific one.

Building an Integrated Biopharma Engine

Beyond its drug pipeline, Valion Bio has made a strategic pivot into manufacturing with the launch of its subsidiary, Velocity Bioworks. Formed from the assets of Scorpius Holdings acquired in December 2025, Velocity is a full-service contract development and manufacturing organization (CDMO) operating out of a state-of-the-art facility in San Antonio.

This move serves two purposes. First, it gives Valion control over the manufacturing of Entolimod™, a critical step for a company moving toward a Biologics License Application (BLA) and commercialization. Second, it taps into the booming biologics CDMO market, which is projected to grow to over $39 billion by 2032, driven by an explosion in complex biologic drugs and the trend of small- and mid-sized biotechs outsourcing manufacturing.

By offering services to third-party companies, Velocity Bioworks creates a new revenue stream that can help fund Valion’s own R&D. However, operating a CDMO brings its own set of legal complexities, from negotiating manufacturing service agreements and managing technology transfers to protecting the intellectual property of both Valion and its clients. Lackey's background in biopharmaceutical transactions and IP strategy directly addresses the legal infrastructure needed to support this dual-pronged business model.

With a significant financing package in place and a new, uniquely qualified legal chief at the helm, Valion Bio is signaling to investors that it has assembled the key components for its ambitious plan. The company is betting that this integrated strategy—combining drug development, in-house manufacturing, and a leadership team that speaks both science and law—will be the formula for success in the competitive field of immunotherapeutics.